Navigating Aetna Fasenra Prior Authorization

Understanding Fasenra (Benralizumab) within Aetna's Framework

Fasenra (benralizumab) is an interleukin-5 (IL-5) receptor alpha antagonist, a biologic medication indicated for severe eosinophilic asthma. As a high-cost specialty injectable, Fasenra typically requires prior authorization across Aetna's commercial, Medicare Advantage, and Medicaid managed care plans. Aetna's Clinical Policy Bulletins (CPBs) will detail the specific medical necessity criteria, including diagnostic requirements, patient selection, and potential step therapy protocols.

Aetna Prior Authorization Submission Channels for Fasenra

The appropriate submission channel for Aetna Fasenra prior authorization depends on whether the drug is covered under the medical or pharmacy benefit. Aetna, a CVS Health company, administers pharmacy benefits through CVS Caremark, while medical benefits are processed through different channels. Klivira's platform is engineered to connect with all relevant Aetna submission points.

Submission Pathways for Aetna Fasenra

• **Medical Benefit PA:** For Fasenra administered under the medical benefit, Aetna routes the majority of precertification requests through the Availity provider portal. X12 278 transactions via clearinghouses are also supported for applicable procedure categories.
• **Pharmacy Benefit PA:** If Fasenra is managed under the pharmacy benefit, submissions typically route through ePA partners such as CoverMyMeds or Surescripts for retail pharmacy claims. For mail-order or case-managed scenarios, CVS Caremark's direct provider portal may be utilized.
• **Specialty Pharmacy Management:** Some specialty injectable medications may route through a dedicated specialty-pharmacy-management workflow. It is critical to verify the current benefit assignment for Fasenra to ensure submission via the correct channel.

Aetna Clinical Policy Bulletins (CPBs) and Medical Necessity Criteria

Aetna's medical necessity criteria for Fasenra, including specific indications, dosing, and duration of therapy, are published as Clinical Policy Bulletins (CPBs) in the public Aetna CPB library. These CPBs are versioned and dated, serving as the canonical source for prior authorization requirements. Prior authorization coordinators must reference the specific CPB number and review date to ensure compliance with the latest criteria, which may include requirements for prior therapies or specific eosinophil counts.

Common Denial Patterns and Appeal Pathways for Specialty Biologics

Prior authorization denials for specialty biologics like Fasenra often stem from medical necessity criteria not being met, insufficient documentation, or failure to adhere to step therapy requirements. Aetna returns denial reasons via X12 835/277 transactions or portal status updates, utilizing standard CARC and RARC vocabularies. Klivira streamlines the documentation submission process to proactively address these common denial triggers.

Aetna Appeal Process for Prior Authorizations

• **Reconsideration:** An initial review of the decision, often requiring additional clinical documentation.
• **Peer-to-Peer Review:** An opportunity for the requesting provider to discuss the clinical rationale with an Aetna medical director.
• **Formal Appeal:** A multi-level process documented in Aetna's provider manual, with expedited pathways for urgent care needs.
• **External Review:** For commercial plans, eligibility follows state external-review programs; for Medicare Advantage, federal Independent Review Organization (IRO) processes apply.

Turnaround Time Considerations for Aetna Fasenra PAs

Prior authorization turnaround times for Aetna Fasenra requests are influenced by several factors. Commercial plans adhere to state-mandated minimums and NCQA Utilization Management accreditation standards, which historically set 15 calendar days for non-urgent decisions. For Medicare Advantage and Medicaid managed care lines (Aetna Better Health), CMS-0057-F mandates 72-hour decisions for standard PA requests and 24-hour decisions for expedited requests, with phased compliance timelines. Klivira's automation helps track these critical deadlines.